Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4
暂无分享,去创建一个
P. Oberoi | D. O'Shannessy | E. Somers | R. Thiel | Leslie M Palmer | R. Heath | L. Marcucci | Pankaj Oberoi
[1] D. O'Shannessy,et al. Expression of Folate Receptor-&agr; (FRA) in Gynecologic Malignancies and its Relationship to the Tumor Type , 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[2] E. Sausville,et al. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. V. van Meerbeeck,et al. Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption. , 2012, Clinical lung cancer.
[4] M. Edelman,et al. Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] D. O'Shannessy,et al. Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease , 2012, SpringerPlus.
[6] J. Beta,et al. HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection. , 2012, Oncology letters.
[7] M. Schummer,et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. , 2012, Gynecologic oncology.
[8] S. Singhal,et al. Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance , 2012, Oncotarget.
[9] Y. Hamuro,et al. Characterization of the Human Folate Receptor Alpha Via Novel Antibody-Based Probes , 2011, Oncotarget.
[10] R. Molina,et al. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. , 2011, Clinical chemistry.
[11] I. Shih,et al. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.
[12] P. Low,et al. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer , 2011, Cellular Oncology.
[13] I. Hellstrom,et al. fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma. , 2011, Expert opinion on medical diagnostics.
[14] Ashok Agarwal,et al. Potential Markers for Detection and Monitoring of Ovarian Cancer , 2011, Journal of oncology.
[15] J. Creaney,et al. Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden , 2010, Clinical Cancer Research.
[16] S. Larson,et al. Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study , 2010, Clinical Cancer Research.
[17] M. Tsao,et al. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] K. Nackaerts,et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. , 2010, American journal of respiratory and critical care medicine.
[19] P. Low,et al. Functional Folate Receptor Alpha Is Elevated in the Blood of Ovarian Cancer Patients , 2009, PloS one.
[20] G. Anderson,et al. Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125 , 2009, Cancer Epidemiology Biomarkers & Prevention.
[21] M. Werner,et al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. , 2008, Anticancer research.
[22] Qin He,et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. , 2008, Gynecologic oncology.
[23] G. Anderson,et al. Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.
[24] Richard G. Moore,et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. , 2008, Gynecologic oncology.
[25] P. Low,et al. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. , 2008, Human pathology.
[26] P. Low,et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. , 2008, Gynecologic oncology.
[27] Thorsten Verch,et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. , 2008, Gynecologic oncology.
[28] M. Sonobe,et al. Expression Status of Folate Receptor α Is Significantly Correlated with Prognosis in Non-Small-Cell Lung Cancers , 2008, Annals of Surgical Oncology.
[29] R. Bast,et al. Early Detection of Ovarian Cancer , 2007, Disease markers.
[30] Richard G. Moore,et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. , 2007, Gynecologic oncology.
[31] Z. Yue,et al. Serum tumour markers in patients with chronic kidney disease , 2007, Scandinavian journal of clinical and laboratory investigation.
[32] Mitchell Ho,et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors , 2006, Molecular Cancer.
[33] Kazuhisa Takahashi,et al. Novel ELISA system for detection of N‐ERC/mesothelin in the sera of mesothelioma patients , 2006, Cancer science.
[34] Mitchell Ho,et al. Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma , 2006, Clinical Cancer Research.
[35] H. Frierson,et al. Comprehensive analysis of HE4 expression in normal and malignant human tissues , 2006, Modern Pathology.
[36] N. Sardesai,et al. Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker , 2006, Cancer Epidemiology Biomarkers & Prevention.
[37] Yinhua Yu,et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. , 2005, Gynecologic oncology.
[38] Jan Holm,et al. Megalin binds and mediates cellular internalization of folate binding protein , 2005, The FEBS journal.
[39] K A Baggerly,et al. New tumor markers: CA125 and beyond , 2005, International Journal of Gynecologic Cancer.
[40] Mitchell Ho,et al. New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA , 2005, Clinical Cancer Research.
[41] P. Low,et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. , 2005, Analytical biochemistry.
[42] Christopher P Crum,et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.
[43] N Urban,et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. , 2004, Gynecologic oncology.
[44] E. Glezer,et al. Clinical and Biological Applications of ECL , 2004 .
[45] Robert C. Bast,et al. Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis , 2004, Clinical Cancer Research.
[46] N. Umesaki,et al. Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion* , 2004, Journal of Biological Chemistry.
[47] A. Musk,et al. Mesothelin-family proteins and diagnosis of mesothelioma , 2003, The Lancet.
[48] Michèl Schummer,et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. , 2003, Cancer research.
[49] N. Ordóñez. Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma , 2003, Modern Pathology.
[50] U Menon,et al. Factors influencing serum CA125II levels in healthy postmenopausal women. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[51] D. Sugarbaker,et al. The α folate receptor is highly activated in malignant pleural mesothelioma , 2001 .
[52] Z. Ye,et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[53] W. Gunning,et al. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[54] A. Russo,et al. Expression of folate binding protein as a prognostic factor for response to platinum‐containing chemotherapy and survival in human ovarian cancer , 1998, International journal of cancer.
[55] G Toffoli,et al. Overexpression of folate binding protein in ovarian cancers , 1997, International journal of cancer.
[56] Markman. The Role of CA-125 in the Management of Ovarian Cancer. , 1997, The oncologist.
[57] I. Pastan,et al. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[58] N. Yamaguchi,et al. Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA (*) , 1995, The Journal of Biological Chemistry.
[59] S. Thylan. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. , 1995, Gynecologic oncology.
[60] C. Meijer,et al. Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue. , 1995, Journal of clinical pathology.
[61] J. Ross,et al. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications , 1994, Cancer.
[62] N. Yamaguchi,et al. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. , 1994, The Journal of biological chemistry.
[63] V. Zurawski,et al. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. , 1992, Cancer research.
[64] L R Coney,et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. , 1992, Cancer research.
[65] D. Goldenberg,et al. Normal tissue reactivity of four anti‐tumor monoclonal antibodies of clinical interest , 1991, International journal of cancer.
[66] P. Kenemans,et al. Comparative Immunohistochemical Study of Four Monoclonal Antibodies Directed Against Ovarian Carcinoma‐Associated Antigens , 1991, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[67] S. Ménard,et al. Immunohistochemical Reactivity of a Monoclonal Antibody Prepared against Human Ovarian Carcinoma on Normal and Pathological Female Genital Tissues , 1989, Tumori.
[68] S. Doniņa,et al. Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case--control study. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[69] H. Labib,et al. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. , 2010, Asian Pacific journal of cancer prevention : APJCP.
[70] M. Maeda,et al. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. , 2008, Oncology reports.
[71] I. Hellstrom,et al. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. , 2008, Advances in experimental medicine and biology.
[72] Mitchell Ho,et al. Mesothelin targeted cancer immunotherapy. , 2008, European journal of cancer.
[73] D. Sugarbaker,et al. The alpha folate receptor is highly activated in malignant pleural mesothelioma. , 2001, The Journal of thoracic and cardiovascular surgery.
[74] P. Bunn,et al. New anti‐lung‐cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.